Drug Profile
Conestat alfa - Pharming Group
Alternative Names: Human C1 esterase inhibitor - Pharming; Recombinant human C1 esterase inhibitor - Pharming; rhC1INH; Rhucin; RuconestLatest Information Update: 28 May 2023
Price :
$50
*
At a glance
- Originator Pharming Group NV
- Class Anti-inflammatories; Antihypertensives; Complement C1 inactivator proteins; Recombinant proteins; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action Complement C1r inhibitors; Complement C1s inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hereditary angioedema
- Phase II COVID 2019 infections; Stroke
- No development reported Delayed graft function; Shock
- Discontinued Acute kidney injury; Preeclampsia; Renal transplant rejection
Most Recent Events
- 28 May 2023 No recent reports of development identified for clinical-Phase-Unknown development in COVID-2019-infections in Switzerland (IV, Infusion)
- 04 Aug 2022 Discontinued - Phase-I/II for Preeclampsia (Prevention) in Australia (unspecified route) as per company decision
- 04 Aug 2022 Discontinued - Phase-I/II for Preeclampsia (Prevention) in Netherlands (unspecified route) as per company decision